AU2006235266B2 - Gammaretrovirus associated with cancer - Google Patents

Gammaretrovirus associated with cancer Download PDF

Info

Publication number
AU2006235266B2
AU2006235266B2 AU2006235266A AU2006235266A AU2006235266B2 AU 2006235266 B2 AU2006235266 B2 AU 2006235266B2 AU 2006235266 A AU2006235266 A AU 2006235266A AU 2006235266 A AU2006235266 A AU 2006235266A AU 2006235266 B2 AU2006235266 B2 AU 2006235266B2
Authority
AU
Australia
Prior art keywords
xmrv
seq
nucleic acid
polypeptide
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2006235266A
Other languages
English (en)
Other versions
AU2006235266A1 (en
AU2006235266A2 (en
Inventor
Graham Casey
Joseph Derisi
Don Ganem
Eric A. Klein
Robert Silverman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cleveland Clinic Foundation
University of California, San Diego
Original Assignee
Cleveland Clinic Foundation
University of California Berkeley
University of California, San Diego
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cleveland Clinic Foundation, University of California Berkeley, University of California, San Diego filed Critical Cleveland Clinic Foundation
Publication of AU2006235266A1 publication Critical patent/AU2006235266A1/en
Publication of AU2006235266A2 publication Critical patent/AU2006235266A2/en
Application granted granted Critical
Publication of AU2006235266B2 publication Critical patent/AU2006235266B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2006235266A 2005-04-07 2006-04-07 Gammaretrovirus associated with cancer Ceased AU2006235266B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US66947305P 2005-04-07 2005-04-07
US60/669,473 2005-04-07
US75180905P 2005-12-19 2005-12-19
US60/751,809 2005-12-19
PCT/US2006/013167 WO2006110589A2 (en) 2005-04-07 2006-04-07 Gammaretrovirus associated with cancer

Publications (3)

Publication Number Publication Date
AU2006235266A1 AU2006235266A1 (en) 2006-10-19
AU2006235266A2 AU2006235266A2 (en) 2006-10-19
AU2006235266B2 true AU2006235266B2 (en) 2010-12-23

Family

ID=37024999

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006235266A Ceased AU2006235266B2 (en) 2005-04-07 2006-04-07 Gammaretrovirus associated with cancer

Country Status (8)

Country Link
US (2) US8263085B2 (enExample)
EP (1) EP1882032A2 (enExample)
JP (2) JP2008538494A (enExample)
AU (1) AU2006235266B2 (enExample)
CA (1) CA2603863A1 (enExample)
MX (1) MX2007012361A (enExample)
NZ (1) NZ562221A (enExample)
WO (1) WO2006110589A2 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2603863A1 (en) 2005-04-07 2006-10-19 The Cleveland Clinic Foundation Gammaretrovirus associated with cancer
JP5564499B2 (ja) * 2008-07-31 2014-07-30 シグマ−タウ・インドゥストリエ・ファルマチェウチケ・リウニテ・ソシエタ・ペル・アチオニ 前立腺癌の進行を予防または減退させるのに有効な組成物
WO2010075414A2 (en) 2008-12-23 2010-07-01 The Cleveland Clinic Foundation Method for detection of xmrv
EP2628803A3 (en) * 2009-02-25 2014-01-01 Cepheid Methods of detecting lung cancer
WO2010132886A1 (en) * 2009-05-15 2010-11-18 The University Of Utah Research Foundation Compositions and methods relating to xmrv-related diseases and conditions
WO2010148323A2 (en) * 2009-06-18 2010-12-23 Whittemore Peterson Institute For Neuro-Immune Disease Diagnosis and treatment of diseases or disorders associated with xenotropic murine leukemia virus
EP2449381A1 (en) * 2009-06-30 2012-05-09 Abbott Laboratories Markers of xmrv infection and uses thereof
WO2011041350A2 (en) * 2009-10-02 2011-04-07 Emory University Xenotropic mulv-related virus (xmrv) compositions and methods of use
WO2011091395A1 (en) * 2010-01-25 2011-07-28 Functional Genetics, Inc. Antibodies for diagnosis and therapeutic treatment of prostate cancer
WO2011092199A1 (en) 2010-01-26 2011-08-04 Institut Gustave Roussy Mutated xmrv env proteins in the immunosuppressive domain
US20110311484A1 (en) * 2010-04-06 2011-12-22 Whittemore Peterson Institute For Neuro-Immune Disease Strains of xenotropic murine leukemia-related virus and methods for detection thereof
EP2913402B1 (en) * 2010-07-16 2017-10-18 Tocagen Inc. Retrovirus detection
WO2012024513A2 (en) * 2010-08-18 2012-02-23 Abbott Laboratories Molecular detection of xmrv infection
WO2012024518A1 (en) * 2010-08-18 2012-02-23 Abbott Laboratories Molecular detection of xmrv infection
WO2012030856A2 (en) * 2010-08-30 2012-03-08 Gen-Probe Incorporated Compositions, methods and reaction mixtures for the detection of xenotropic murine leukemia virus-related virus
US9107892B2 (en) * 2010-10-28 2015-08-18 University of Pittsburgh—of the Commonwealth System of Higher Education Identification of a novel retrovirus in patients with benign prostatic hyperplasia
GB201019043D0 (en) 2010-11-10 2010-12-22 Protea Biopharma N V Use of 2',5'-oligoadenylate derivative compounds
WO2012103355A2 (en) 2011-01-26 2012-08-02 Cepheid Methods of detecting lung cancer
EP2561879A1 (en) 2011-08-23 2013-02-27 Protea Biopharma N.V. Macrophage activating factor for use in the treatment of chronic fatigue syndrome (CFS) and CFS-related diseases and disorders
US20130065222A1 (en) * 2011-08-30 2013-03-14 Gen-Probe Incorporated Compositions, methods and reaction mixtures for the detection of murine leukemia virus-related virus
US20140272993A1 (en) * 2013-03-15 2014-09-18 The Translational Genomics Research Institute Method of sequencing a full microrna profile from cerebrospinal fluid
US20140303025A1 (en) * 2013-03-15 2014-10-09 The Translational Genomics Research Institute Methods for the diagnosis and prognosis of neurodegenerative diseases
WO2016143226A1 (ja) * 2015-03-10 2016-09-15 株式会社島津製作所 反応場を制限したプロテアーゼ分解反応による抗体からペプチド断片を得る方法
CN114898802B (zh) * 2022-07-14 2022-09-30 臻和(北京)生物科技有限公司 基于血浆游离dna甲基化测序数据的末端序列频率分布特征确定方法、评价方法及装置

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0464533B1 (de) 1990-06-28 1998-07-29 Hoechst Aktiengesellschaft Fusionsproteine mit immunglobulinanteilen, ihre Herstellung und Verwendung
CA2468903A1 (en) * 2001-12-07 2004-05-06 Chiron Corporation Endogenous retrovirus up-regulated in prostate cancer
CA2603863A1 (en) 2005-04-07 2006-10-19 The Cleveland Clinic Foundation Gammaretrovirus associated with cancer
WO2010075414A2 (en) 2008-12-23 2010-07-01 The Cleveland Clinic Foundation Method for detection of xmrv
US20110151431A1 (en) 2009-06-18 2011-06-23 Whittemore Peterson Institute For Neuro-Immune Disease Detection of xenotropic murine leukemia virus
WO2010148323A2 (en) 2009-06-18 2010-12-23 Whittemore Peterson Institute For Neuro-Immune Disease Diagnosis and treatment of diseases or disorders associated with xenotropic murine leukemia virus
EP2449381A1 (en) 2009-06-30 2012-05-09 Abbott Laboratories Markers of xmrv infection and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ANTOINE, M. et. al. UniProt Database Accession number Q9WLJ4 *
CHO, B., et. al. (1995) Journal of Virology 69(11):7138-46 *

Also Published As

Publication number Publication date
EP1882032A2 (en) 2008-01-30
MX2007012361A (es) 2008-02-11
US8263085B2 (en) 2012-09-11
AU2006235266A1 (en) 2006-10-19
CA2603863A1 (en) 2006-10-19
US20130040369A1 (en) 2013-02-14
WO2006110589A8 (en) 2007-03-01
NZ562221A (en) 2011-06-30
JP2013046619A (ja) 2013-03-07
WO2006110589A2 (en) 2006-10-19
WO2006110589A3 (en) 2007-01-11
JP2008538494A (ja) 2008-10-30
AU2006235266A2 (en) 2006-10-19
US20100166797A1 (en) 2010-07-01

Similar Documents

Publication Publication Date Title
US8263085B2 (en) Gammaretrovirus associated with cancer
Dewannieux et al. Identification of an infectious progenitor for the multiple-copy HERV-K human endogenous retroelements
Winkler et al. Characterization of the genome of feline foamy virus and its proteins shows distinct features different from those of primate spumaviruses
Łopata et al. Porcine endogenous retrovirus (PERV)–molecular structure and replication strategy in the context of retroviral infection risk of human cells
EP1578919B1 (en) Endogenous retrovirus up-regulated in prostate cancer
JP4824731B2 (ja) ヒト内因性レトロウイルスのエンベロープタンパク質の発現を検出する方法、並びに上記タンパク質をコードする遺伝子の使用
Alin et al. Amino acid substitutions in the CA protein of Moloney murine leukemia virus that block early events in infection
Nishizawa et al. An avian transforming retrovirus isolated from a nephroblastoma that carries the fos gene as the oncogene
US20120021403A1 (en) Human Endogenous Retrovirus with Foamy-Like Properties and Uses Thereof
Ruggieri et al. Human endogenous retrovirus HERV-K (HML-2) encodes a stable signal peptide with biological properties distinct from Rec
Merregaert et al. Nucleotide sequence of a radiation leukemia virus genome
JP2002542834A (ja) レトロウイルスベクターでのｉｒｅｓ転写カセットからの異種遺伝子群の発現
Schneiderman et al. The Japanese feral mouse Pit1 and Pit2 homologs lack an acidic residue at position 550 but still function as gibbon ape leukemia virus receptors: implications for virus binding motif
Delviks-Frankenberry et al. Generation of multiple replication-competent retroviruses through recombination between PreXMRV-1 and PreXMRV-2
Stewart et al. trans-Acting viral protease is necessary and sufficient for activation of avian leukosis virus reverse transcriptase
AU5829201A (en) An infective endogenous retrovirus and its association with demyelinating diseases and other diseases
Molinaro RNA activators of the RNase L system in prostate cancer
US20040132009A1 (en) Foamy virus mutant reverse transcriptase
Retroviruses Generation of Multiple
Subgroup Evidence of Avian Leukosis Virus
Zhao Characterization of new factors involved in feline leukemia virus (FELV)-mediated leukemogenesis
Lee Reconstitution and Characterization of Human Endogenous Retrovirus-K
Ellis Evolutionary and functional studies of the mouse retroviral restriction gene, Fv1
DeMartini et al. Analysis of Integration Sites of Jaagsiekte
Bishop The interactions of the viral restriction gene, Fv1, and its target

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 26 NOV 2007

NA Applications received for extensions of time, section 223

Free format text: AN APPLICATION TO EXTEND THE TIME FROM 19 OCT 2006 TO 19 DEC 2007 IN WHICH TO COMPLY WITH SECTION 6(C) HAS BEEN FILED .

NB Applications allowed - extensions of time section 223(2)

Free format text: THE TIME IN WHICH TO COMPLY WITH SECTION 6(C) HAS BEEN EXTENDED TO 19 DEC 2007.

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired